SKIN SENSITIVITY AND TRANSDERMAL DRUG-DELIVERY - A REVIEW OF THE PROBLEM

被引:19
作者
CARMICHAEL, AJ
机构
[1] Department of Dermatology, South Cleveland Hospital, Middlesbrough, TS4 3BW, Marton Road Cleveland
关键词
D O I
10.2165/00002018-199410020-00004
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Transdermal devices are now marketed for the delivery of systemic medication through the skin. Advantages associated with transdermal drug delivery include avoidance of first-pass metabolism and improved patient compliance. Drugs currently available by this route include scopolamine (hyoscine), nitroglycerin (glyceryl trinitrate!, estradiol, nicotine and clonidine. This novel development has brought in its wake a specific constellation of skin sensitivity problems, which vary widely in incidence between drugs. Varying the site of drug administration to minimise these reactions is important. Any eczematous reaction can be treated with a moderately potent topical steroid. Tolerance to oral challenge in those with topical sensitivity occurs, but caution is still advocated before proceeding to this step. The increasing use of transdermal drug delivery systems across many specialities means that problems of skin sensitivity are of growing relevance to the dermatologist, the hospital specialist and the primary care physician.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 67 条
[51]  
Scheper R.J., von Blomberg B.M.E., de Groot J., Geoptar A.R., Lang M., Et al., Low allergenicity of clonidine impedes studies of sensitization mechanisms in guinea pig models, Contact Dermatitis, 23, pp. 81-89, (1990)
[52]  
Scheuplein R.J., Blank I.H., Permeability of the skin, Physiological Reviews, 51, pp. 702-747, (1971)
[53]  
Schwartz B.K., Clendenning W.E., Allergic contact dermatitis from hydroxypropyl cellulose in a transdermal estradiol patch, Contact Dermatitis, 18, pp. 106-107, (1988)
[54]  
Sebel P.S., Barrett C.W., Kirk C.J.C., Heykants J., Transdermal absorption of fentanyl and sufentanil in man, European Journal of Clinical Pharmacology, 32, pp. 529-531, (1987)
[55]  
Shaw J.E., Prevo M.E., Amkraut A.A., Testing of controlled-release transdermal dosage forms, Archives of Dermatology, 123, pp. 1548-1556, (1987)
[56]  
Shaw J.E., Urquhart J., Transdermal drug administration — a nuisance becomes an opportunity, British Medical Journal, 283, pp. 875-876, (1981)
[57]  
Topaz O., Abraham D., Severe allergic contact dermatitis secondary to nitroglycerin in a transdermal therapeutic system, Annals of Allergy, 59, pp. 365-366, (1987)
[58]  
Trozak D.J., Delayed hypersensitivity to scopolamine delivered by a transdermal device, Journal of the American Academy of Dermatology, 13, pp. 247-251, (1985)
[59]  
Utian W.H., Transdermal estradiol overall safety profile, American Journal of Obstetrics and Gynecology, 156, pp. 1335-1338, (1987)
[60]  
Utian W.H., Panel discussion III, American Journal of Obstetrics and Gynecology, 156, pp. 1338-1341, (1987)